Enzon Pharmaceuticals Inc represents values of innovation, commitment to scientific excellence, and a dedication to improving patient outcomes. With a corporate philosophy centered around research and development, Enzon Pharmaceuticals Inc aims to discover and develop novel therapies that address unmet medical needs. By leveraging its expertise and advancing cutting-edge technologies, the company strives to deliver transformative treatments for complex diseases. Enzon Pharmaceuticals Inc's commitment to delivering differentiated therapeutic solutions is reflected in its unwavering focus on scientific rigor, collaboration, and patient-centricity. Embracing its mission, Enzon Pharmaceuticals Inc continuously endeavors to make a positive impact on the lives of patients worldwide.

Enzon Pharmaceuticals Inc is primarily present in the United States. While its operations are primarily focused in the US, Enzon also has a presence in select international markets. However, its primary focus remains on the US market where it develops, manufactures, and commercializes pharmaceutical products.

Enzon Pharmaceuticals Inc has achieved several significant milestones. These include successful completion of clinical trials for its novel drug candidates, securing FDA approvals for key products, and establishing strategic partnerships with leading pharmaceutical companies. Additionally, Enzon Pharmaceuticals Inc has witnessed noteworthy advancements in research and development, resulting in the discovery of innovative therapies. These accomplishments have reinforced the company's position as a prominent player in the pharmaceutical industry. Overall, Enzon Pharmaceuticals Inc has demonstrated notable progress in its pursuit of developing groundbreaking healthcare solutions.

Enzon Pharmaceuticals Inc is a biopharmaceutical company that was founded in 1981. It specializes in developing and commercializing innovative therapies for life-threatening diseases. Throughout its history, Enzon Pharmaceuticals Inc has focused on advancing therapeutic options for patients with cancer, infectious diseases, and immune-mediated disorders. The company has a diverse portfolio of products and technologies, including proprietary technologies for protein delivery and targeted delivery systems. Enzon Pharmaceuticals Inc has also established collaborations and partnerships to enhance its research and development efforts. With its commitment to scientific advancements and patient care, Enzon Pharmaceuticals Inc has become a reputable player in the pharmaceutical industry.

The main competitors of Enzon Pharmaceuticals Inc in the market include Pfizer, Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG.

Enzon Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Enzon Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with rare diseases. Their business model centers around identifying unmet medical needs and leveraging their expertise in drug development to bring innovative treatments to market. Enzon Pharmaceuticals works collaboratively with research institutions, healthcare professionals, and patients to advance their pipeline of novel therapies. By combining cutting-edge science and clinical expertise, they strive to improve the lives of individuals suffering from rare diseases. Enzon Pharmaceuticals Inc is committed to making a meaningful impact in the pharmaceutical industry through their dedication to research, development, and patient care.

Pašreizējais KGV Enzon Pharmaceuticals nevar tikt aprēķināts.

KUV šobrīd Enzon Pharmaceuticals nevar aprēķināt.

AlleAktien kvalitātes vērtējums šobrīd nevar tikt aprēķināts priekš Enzon Pharmaceuticals.

Pašreiz nevar aprēķināt apgrozījumu Enzon Pharmaceuticals.

Pašlaik peļņa Enzon Pharmaceuticals nevar tikt aprēķināta.

Enzon Pharmaceuticals Inc is a biopharmaceutical company based in New Jersey that specializes in the development of innovative therapeutics. The company was founded in 1981 and focuses on the areas of cancer, infectious diseases, and autoimmune disorders. Enzon works on the development of proteins and antibodies to block or destroy disease-causing molecules or cells. Enzon has two main business segments: biopharmaceuticals and utility cell. The biopharmaceutical segment focuses on the research, development, and marketing of therapeutic agents derived from natural proteins or produced as recombinant proteins. The utility cell segment offers cell culture products that can be used for research and the therapeutics market. Enzon has several products on the market, including Adagen (pegademase bovine), an enzyme replacement therapy for patients with ADA deficiency, a rare genetic condition. Enzon also manufactures and markets a polyethylene glycol (PEG) formulation of interferon alpha, PEG-Intron. Enzon has a strategic alliance with pharmaceutical company Pfizer to utilize Enzon's PEG technology for the development of drugs to treat cancer and other diseases. Enzon is currently engaged in multiple projects in the field of cancer therapy, including a phase 1 study of a novel immunotherapy for patients with metastatic melanoma and a phase 1b study of a novel antibody-drug conjugate (ADC) therapy for patients with advanced breast cancer. Enzon is also working on the development of antibodies against CD19, a surface protein expressed on certain blood cancer cells. Enzon has a strong pipeline of new therapeutic approaches for a variety of diseases such as cancer, autoimmune disorders, and infections. The company pursues a strategy of collaboration and alliances with other leading pharmaceutical and biopharmaceutical companies to promote innovation and growth. Overall, Enzon offers a comprehensive approach to the development of biopharmaceuticals and is on track to become one of the leading companies in the fields of cancer, autoimmune disorders, and infections. With its strong pipeline, innovative technology, and extensive experience in the development of biopharmaceuticals, Enzon is positioning itself for future growth and success.

Enzon Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Enzon Pharmaceuticals vai uzņēmums nedod dividendes.

Enzon Pharmaceuticals ISIN ir US2939041081.

Enzon Pharmaceuticals WKN ir 873997.

Enzon Pharmaceuticals simbols ir ENZN.

Pēdējo 12 mēnešu laikā Enzon Pharmaceuticals maksāja dividendes 0,18 USD apmērā. Tas atbilst aptuveni 128,57 % dividendes ražībai. Nākamajos 12 mēnešos Enzon Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Enzon Pharmaceuticals pašreizējā dividendu rentabilitāte ir 128,57 %.

Enzon Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos janvāris, oktobris, marts, oktobris.

Enzon Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Enzon Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Enzon Pharmaceuticals apmērā 0,12 USD, kas tika izmaksāta 15.10.2019., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 30.09.2019..

Pēdējās dividendes izmaksa notika 15.10.2019..

Gadā 2023, Enzon Pharmaceuticals izmaksāja 0 USD dividendes.

Enzon Pharmaceuticals dividendes tiek izmaksātas USD.